Evaluation of the performance of the GoldMag SARS-CoV-2 IgG/IgM test in the detection of Immunoglobulin G in COVID-19 patients at the Epidemiological Treatment Center of Gbessia

Abstract

Objective: To determine the clinical performance of a rapid serological test in the detection of antibodies in patients COVID-19 at CTEPI-Gbessia.

Method: This was a descriptive and analytical cross-sectional study of RT-PCR positive patients hospitalized at CTEPI-Gbessia from November 20, 2020 to February 28, 2021. An analysis of intrinsic and extrinsic performance was conducted to measure the validity of the test.

Results: The study included 69 patients tested positive to RT-PCR and hospitalized at CTEPI-Gbessia. The patients included were predominantly male, with a mean age of 38.7 ± 15 years. Of all the patients included, 40.60% had at least one symptom of the disease before admission to CTEPI. Headache (75%), fatigue (71, 42%), fever (46,40%) were the most cited symptoms. Among symptomatic patients, 60% had hypertension, 71.43% had asthma and 100% had diabetes. The serological (T) IgG/IgM RDT showed a sensitivity of 43.90% (CI95%: 32.19 - 55.60) and a specificity of 85.71% (CI95%: 77.45 - 93.96) with NPV (51.06%) and PPV (81.81%).

Conclusion: During the three months of data collection at CTEPI-Gbessia, we evaluated the diagnostic capacity of the GoldMag SARS-CoV-2 IgG/IgM test in the detection of antibodies in the serum of hospitalised patients and a moderate sensitivity was reported. To enhance the analytical performance of the test it will be wise to use it on symptomatic patients